Soft tissue sarcoma: Clinical practice guidelines in oncology™

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 5, Issue 4, 2007, Pages 364-399

  Demetri, George D ^a   Baker, Laurence H ^a   Benjamin, Robert S ^a   Casper, Ephraim S ^a   Conrad III, Ernest U ^a   D'Amato, Gina Z ^a   DeLaney, Thomas F ^a   Ettinger, David S ^a   Heck Jr , Robert ^a   Heslin, Martin J ^a   Hutchinson, Ray J ^a   Jacobs, Charlotte D ^a   Kiel, Krystyna ^a   Kraybill, William G ^a   Letson, G Douglas ^a   O'Donnell, Richard J ^a   Paz, I Benjamin ^a   Pfeifer, John ^a   Pollock, Raphael E ^a   Randall, R Lor ^a   Sasson, Aaron R ^a   Schupak, Karen D ^a   Tyler, Douglas S ^a   Von Mehren, Margaret ^a   Wayne, Jeffrey ^a   more..

^a NONE

Author keywords

Chemotherapy; Desmoid tumor; Gastrointestinal stromal tumors; NCCN Clinical Practice Guidelines; Radiation therapy; Retroperitoneal sarcomas; Soft tissue extremity sarcoma; Soft tissue sarcoma; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; CELECOXIB; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; IFOSFAMIDE; IMATINIB; INTERFERON; MESNA; METHOTREXATE; NAVELBINE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PLACEBO; SULINDAC; SUNITINIB; TAMOXIFEN; TOREMIFENE; TRABECTEDIN; VINBLASTINE;

BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; LOW DRUG DOSE; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; SOFT TISSUE SARCOMA; TUMOR BIOPSY; UNITED STATES;

EID: 34248232454     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2007.0034     Document Type: Conference Paper

References (144)

1. Pisters PW, Casper ES, Mann GN, et al. Soft tissue sarcomas. In: Pazdur R, Hoskins WJ, Coia LR, Wagman LD, eds. Cancer Management: A Multidisciplinary Approach, 9th ed. Manhasset, NY: CMP Healthcare Media; 2005:585-614.
2. Cormier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin 2004;54:94-109.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
4. Pisters P. Staging and prognosis. In: Pollock RE, ed. American Cancer Society Atlas of Clinical Oncology: Soft Tissue Sarcomas. Hamilton, Ontario, Canada: BC Decker: 2002:80-88.
5. Kindblom LG, Meis-Kindblom J, Bümming P, et al. Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal cell tumors (GIST): a population based study of 600 cases [abstract]. Ann Oncol 2002;13(suppl 5):157. Abstract 577O.
6. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-465.
7. Zahm SH, Fraumeni JF Jr. The epidemiology of soft tissue sarcoma. Semin Oncol 1997;24:504-514.
8. Coindre JM, Terrier P, Guillou L, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001;91:1914-1926.
9. Greene FL, Page DL, Fleming ID, et al., eds. AJCC Cancer Staging Manual, 6th ed. New York: Springer-Verlag; 2002.
10. Dileo P, Demetri GD. Update on new diagnostic and therapeutic approaches for sarcomas. Clin Adv Hematol Oncol 2005;3:781-791.
11. Borden EC, Baker LH, Bell RS, et al. Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res 2003;9:1941-1956.
12. Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med 2005;353:701-711.
13. Lewis JJ, Leung D, Espat J, et al. Effect of reresection in extremity soft tissue sarcoma. Ann Surg 2000;231:655-663.
14. Zagars GK, Ballo MT, Pisters PW, et al. Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. Cancer 2003;97:2544-2553.
15. National Institutes of Health consensus development panel on limb-sparing treatment of adult soft-tissue sarcomas and osteosarcomas. Proceedings of Cancer Treatment Symposium. 1985:1-5.
16. Ghert MA, Abudu A, Driver N, et al. The indications for and the prognostic significance of amputation as the primary surgical procedure for localized soft tissue sarcoma of the extremity. Ann Surg Oncol 2005;12:10-17.
17. Williard WC, Hajdu SI, Casper ES, Brennan MF. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg 1992;215:269-275.
18. DeLaney TF, Trofimov AV, Engelsman M, Suit HD. Advanced-technology radiation therapy in the management of bone and soft tissue sarcomas. Cancer Control 2005;12:27-35.
19. Sadoski C, Suit HD, Rosenberg A, et al. Preoperative radiation, surgical margins, and local control of extremity sarcomas of soft tissues. J Surg Oncol 1993;52:223-230.
20. Davis AM, O'Sullivan B, Bell RS, et al. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol 2002;20:4472-4477.
21. Alektiar KM, Velasco J, Zelefsky MJ, et al. Adjuvant radiotherapy for margin-positive high-grade soft tissue sarcoma of the extremity. Int J Radiat Oncol Biol Phys 2000;48:1051-1058.
22. Alektiar KM, Leung D, Zelefsky MJ, et al. Adjuvant brachytherapy for primary high-grade soft tissue sarcoma of the extremity. Ann Surg Oncol 2002;9:48-56.
23. Tran QNH, Anne KC, Gottschalk AR, et al. Clinical outcomes of intraoperative radiation therapy for extremity sarcomas. Sarcoma 2006:1-6. Epub 2006:91671.
24. Clasby R, Tilling K, Smith MA, et al. Variable management of soft tissue sarcoma: regional audit with implications for specialist care. Br J Surg 1997;84:1692-1696.
25. Heslin MJ, Smith JK. Imaging of soft tissue sarcomas. Surg Oncol Clin N Am 1999;8:91-107.
26. Demas BE, Heelan RT, Lane J, et al. Soft-tissue sarcomas of the extremities: comparison of MR and CT in determining the extent of disease. AJR Am J Roentgenol 1988;150:615-620.
27. Hanna SL, Fletcher BD. MR imaging of malignant soft-tissue tumors. Magn Reson Imaging Clin N Am 1995;3:629-650.
28. Schuetze SM. Utility of positron emission tomography in sarcomas. Curr Opin Oncol 2006;18:369-373.
29. Folpe AL, Lyles RH, Sprouse JT, et al. (F-18) Fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 2000;6:1279-1287.
30. Schuetze SM, Rubin BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005;103:339-348.
31. Eary JF, O'Sullivan F, Powitan Y, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging 2002;29:1149-1154.
32. Brenner W, Eary JF, Hwang W, et al. Risk assessment in liposarcoma patients based on FDG PET imaging. Eur J Nucl Med Mol Imaging 2006;33:1290-1295.
33. Geer RJ, Woodruff J, Casper ES, et al. Management of small soft-tissue sarcoma of the extremity in adults. Arch Surg 1992;127: 1285-1289.
34. Karakousis CP, Emrich LJ, Rao U, et al. Limb salvage in soft tissue sarcomas with selective combination of modalities. Eur J Surg Oncol 1991;17:71-80.
35. Lindberg RD, Martin RG, Romsdahl MM, et al. Conservative surgery and postoperative radiotherapy in 300 adults with soft-tissue sarcomas. Cancer 1981;47:2391-2397.
36. Yang JC, Chang AE, Baker AR, et al. A randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998;16: 197-203.
37. Pisters PW, Harrison LB, Leung DH, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996;14:859-868.
38. Suit HD, Spiro I. Role of radiation in the management of adult patients with sarcoma of soft tissue. Semin Surg Oncol 1994;10: 347-356.
39. Barkley HT, Martin RG, Romsdahl MM, et al. Treatment of soft tissue sarcomas by preoperative irradiation and conservative surgical resection. Int J Rad Oncol Biol Phys 1988;14:693-699.
40. Wilson AN, Davis A, Bell RS, et al. Local control of soft tissue sarcoma of the extremity: the experience of a multidisciplinary sarcoma group with definitive surgery and radiotherapy. Eur J Cancer 1994;30A:746-751.
41. O'Sullivan B, Davis A, Turcotte R, et al. Five-year results of a randomized phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma [abstract]. J Clin Oncol 2004;22(14 suppl): Abstract 9007.
42. Kraybill WG, Harris J, Spiro IJ, et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group trial 9514. J Clin Oncol 2006;24:619-625.
43. Pisters PWT, Patel SR, Varma DGK, et al. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J Clin Oncol 1997;15: 3481-3487.
44. Spiro IJ, Gebhardt MC, Jennings LC, et al. Prognostic factors for local control of sarcomas of the soft tissues managed by radiation and surgery. Semin Oncol 1997;24:540-546.
45. Rosenberg SA, Tepper JE, Glatstein EJ, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982;196:305-315.
46. Grobmyer SR, Maki RG, Demetri GD, et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol 2004;15:1667-1672.
47. DeLaney TF Spiro IJ, Suit HD, et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 2003;56:1117-1127.
48. Pisters PW, Ballo MT, Patel SR. Preoperative chemoradiation treatment strategies for localized sarcoma. Ann Surg Oncol 2002;9:535-542.
49. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997;350:1647-1654.
50. Maki RG. Role of chemotherapy in patients with soft tissue sarcomas. Expert Rev Anticancer Ther 2004;4:229-236.
51. Spira AI, Ettinger DS. The use of chemotherapy in soft-tissue sarcomas. Oncologist 2002;7:348-359.
52. Bramwell VHC, Rouesse J, Steward W, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma - reduced local recurrence but no improvement in survival: a study of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1994;12:1137-1149.
53. Cormier JN, Huang X, Xing Y, et al. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol 2004;22:4567-4574.
54. Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001;19:1238-1247.
55. Frustaci S, De Paoli A, Bidoli E, et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 2003;65(suppl 2):80-84.
56. Lindner LH, Schlemmer M, Hohenberger P, et al. First interim report on the randomized EORTC 62961/ESHO RHT 95 Intergroup Study (phase III) combined with regional hyperthermia (RHT) versus chemotherapy alone in the treatment of high-risk soft tissue sarcomas (HR STS) in adults [abstract]. J Clin Oncol 2004;22(14 suppl): Abstract 9015.
57. Alektiar KM, Leung D, Zelefsky MJ, Brennan MF. Adjuvant radiation for stage II B soft tissue sarcoma of the extremity. J Clin Oncol 2002;20:1643-1650.
58. Singer S, Antman KH, Corson JM, et al. Long-term salvageability for patients with locally recurrent soft-tissue sarcomas. Arch Surg 1992;127:548-553.
59. Meric F, Hess KR, Varma DG, et al. Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer 2002;95:1120-1126.
60. Bramwell VHC, Anderson D, Charette ML and the Sarcoma Disease Site Group. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2003;3:CD003293.
61. Elias A, Ryan L, Sulkes A, et al. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989;7:1208-1216.
62. Antman KH, Elias A. Dana-Farber Cancer Institute studies in advanced sarcoma. Semin Oncol 1990;1(suppl 2):7-15.
63. Zalupski M, Metch B, Balcerzak S, et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group Study. J Natl Cancer Inst 1991;83:926-932.
64. Edmonson J, Ryan L, Blum R, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269-1275.
65. Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993;11:1276-1285.
66. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organisation for Research and Treatment of Cancer soft tissue and bone sarcoma group. J Clin Oncol 1995;13:1537-1545.
67. Siehl J, Thiel E, Schmittel A, et al. Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma. Cancer 2005;104:611-617.
68. Siehl JM, Thiel E, Schmittel A, et al. Liposomal anthracyclines and ifosfamide in the first line treatment of advanced soft tissue sarcomas: a two cohort phase II study [abstract]. J Clin Oncol 2006;24(18 suppl): Abstract 9563.
69. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002;20:2824-2831.
70. Leu KM, Ostruszka LJ, Schewach D, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 2004;22:1706-1712.
71. Bay JO, Ray-Coquard I, Fayette J, et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: retrospective analysis. Int J Cancer 2006;119:706-711.
72. Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005;23:5484-5492.
73. Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004;22:1480-1490.
74. Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET 743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group Trial. J Clin Oncol 2005;23:576-584.
75. Grunhagen DJ, Brunstein F, ten Hagen TL, et al. TNF-based isolated limb perfusion: a decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas. Cancer Treat Res 2004;120:65-79.
76. Grunhagen DJ, de Wilt JH, Graveland WJ, et al. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-α and melphalan for limb-threatening soft tissue sarcoma. Cancer 2006;106: 1776-1784.
77. Whooley BP, Mooney MM, Gibbs JF, Kraybill WG. Effective follow-up strategies in soft tissue sarcoma. Semin Surg Oncol 1999;17:83-87.
78. Whooley BP, Gibbs JF, Mooney MM, et al. Primary extremity sarcoma: what is the appropriate follow-up? Ann Surg Oncol 2000;7:9-14.
79. Kane JM III. Surveillance strategies for patients following surgical resection of soft tissue sarcomas. Curr Opin Oncol 2004;16: 328-332.
80. Lewis JJ, Leung DHY, Casper ES, et al. Multifactorial analysis of long term follow-up (more than 5 years) of primary extremity sarcoma. Arch Surg 1999;134:199-194.
81. Fleming JB, Cantor SB, Varma DG, et al. Utility of chest computed tomography for staging in patients with T1 extremity soft tissue sarcomas. Cancer 2001;92:863-868.
82. Raut C, Pisters PWT. Retroperitoneal sarcomas: combined-modality treatment approaches. J Surg Oncol 2006;94:81-87.
83. Singer S, Corson JM, Demetri GD, et al. Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma. Ann Surg 1995;221:185-195.
84. Mendenhall WM, Zlotecki RA, Hochwald SN, et al. Retroperitoneal soft tissue sarcoma. Cancer 2005;104:669-675.
85. Windham CT, Pisters PWT. Retroperitoneal sarcomas. Cancer Control 2005;12:36-43.
86. Pawlik TM, Pisters PW, Mikula L, et al. Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol 2006;13:508-517.
87. Sanborn RE, Blanke C. Gastrointestinal stromal tumors and the evolution of targeted therapy. Clin Adv Hematol Oncol 2005;3: 647-657.
88. D'Amato G, Steinert DM, McAuliffe JC, Trent JC. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 2005;12:44-56.
89. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-710.
90. Emory TS, Sobin LH, Lukes L, et al. Prognosis of gastrointestinal smooth muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999;23:82-87.
91. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
92. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomized trial. Lancet 2004;364:1127-1134.
93. Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-Z 571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003;39:2006-2011.
94. Rankin C, Von Mehren M, Blanke C, et al. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST phase III Sarcoma Group Study S0033 [abstract]. J Clin Oncol 2004;22(14 suppl): Abstract 9005.
95. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro intestinal stromal tumors crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005;41:1751-1757.
96. Demetri GD, Desai J, Fletcher J A, et al. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) [abstract]. J Clin Oncol 2004;22(14 suppl): Abstract 3001.
97. Maki RG, Fletcher JA, Heinrich MC, et al. Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST) [abstract]. J Clin Oncol 2005;23(16 suppl): Abstract 9011.
98. Demetri G, van Oosterom A, Garrett C, et al. Improved survival and sustained clinical benefit with SU11248 (SU) in pts with GIST after failure of imatinib mesylate (IM) therapy in a phase III trial [abstract]. 2006 Gastrointestinal Cancers Symposium 2006: Abstract 8.
99. Casali PG, Garrett CR, Blackstein ME, et al. Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance [abstract]. J Clin Oncol 2006;24(18 suppl): Abstract 9513.
100. Demetri GD, Benjamin R, Blanke CD, et al. NCCN Task Force Report: optimal management of patients with gastrointestinal stromal tumor (GIST) - expansion and update of NCCN Clinical Practice Guidelines. J Natl Compr Cane Netw 2004;2(suppl 1):S1-26.
101. Blackstein ME, Rankin C, Fletcher C, et al. Clinical benefit of imatinib in patients (pts) with metastatic gastrointestinal stromal tumors (GIST) negative for the expression of CD117 in the S0033 trial [abstract]. J Clin Oncol 2005;23(16 suppl): Abstract 9010.
102. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-58.
103. Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004;11:465-475.
104. Gold JS, Dematteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg 2006;244: 176-184.
105. Van Den Abbeele AD, Badawi RD, Manola J, et al. Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG PET scanning [abstract]. J Clin Oncol 2004;22(14 suppl): Abstract 3012.
106. Le Cesne A, Perol D, Ray-Coquard I, et al. Interruption of imatinib (IM) in GIST patients with advanced disease: updated results of the prospective French Sarcoma Group randomized phase III trial on survival and quality of life [abstract]. J Clin Oncol 2005;23(16 suppl): Abstract 9031.
107. Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006;24:2325-2331.
108. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-1338.
109. Scott RJ, Froggatt NJ, Trembath RC, et al. Familial infiltrative fibromatosis (desmoid tumours) (MIM135290) caused by a recurrent 3′ APC gene mutation. Hum Mol Genet 1996;5: 1921-1924.
110. Friedl W, Caspari R, Sengteller M, et al. Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families. Gut 2001;48: 515-521.
111. Pignatti G, Barbanti Brodano G, Ferrari D, et al. Extraabdominal desmoid tumor. A study of 83 cases. Clin Orthop Relat Res 2000;375:207-213.
112. Posner MC, Shiu MH, Newsome JL, et al. The desmoid tumor. Not a benign disease. Arch Surg 1989;124:191-196.
113. Sorensen A, Keller J, Nielsen OS, et al. Treatment of aggressive fibromatosis: a retrospective study of 72 patients followed for 1-27 years. Acta Orthop Scand 2002;73:213-219.
114. Godwin Y, McCulloch TA, Sully L. Extra-abdominal desmoid tumor of the breast: review of the primary management and the implications for breast reconstruction. Br J Plast Surg 2001;54:268-271.
115. Yamaguchi H, Sakakibara T, Hino M, et al. A case of fibromatosis of the breast. Breast Cancer 2002;9:175-178.
116. Kouriefs C, Leris AC, Mokbel K, et al. Infiltrating fibromatosis of the breast: a potential pitfall. Int J Clin Pract 2002;56:401-402.
117. Biermann JS. Desmoid tumors. Curr Treat Options Oncol 2000;1:262-266.
118. Pritchard DJ, Nascimento AG, Petersen IA, et al. Local control of extra-abdominal desmoid tumors. J Bone Joint Surg Am 1996;78:848-854.
119. Ballo MT, Zagars GK, Pollack A, et al. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 1999;17:158-167.
120. Stojadinovic A, Hoos A, Karpoff HM, et al. Soft tissue tumors of the abdominal wall. Analysis of disease patterns and treatment. Arch Surg 2001;136:70-79.
121. Gronchi A, Casali PG, Mariani L, et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol 2003;21:1390-1397.
122. Lewis JJ, Boland PJ, Leung DH, et al. The enigma of desmoid tumors. Ann Surg 1999;229:866-872.
123. Ballo MT, Zagars GK, Pollack A. Radiation therapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys 1998;42:1007-1014.
124. Schulz Ertner D, Zierhut D, Mende U, et al. The role of radiation therapy in the management of desmoid tumors. Strahlenther Onkol 2002;178:78-83.
125. Kiel KD, Suit HD. Radiation therapy in the treatment of aggressive fibromatoses (desmoid tumors). Cancer 1984;54: 2051-2055.
126. Janinis J, Patriki M, Vini L, et al. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol 2003;14:181-190.
127. Wilcken N, Tattersall MH. Endocrine therapy for desmoid tumors. Cancer 1991;68:1384-1388.
128. Thomas S, Datta-Gupta S, Kapur BM. Treatment of recurrent desmoid tumor with tamoxifen. Aust N Z J Surg 1990;60:919-921.
129. Izes JK, Zinman LN, Larsen CR. Regression of large pelvic desmoid tumor by tamoxifen and sulindac. Urology 1996;47:756-759.
130. Waddell WR, Gerner RE, Reich MP. Nonsteroid anti-inflammatory drugs and tamoxifen for desmoid tumors and carcinoma of the stomach. J Surg Oncol 1983;22:197-211.
131. Lackner H, Urban C, Kerbl R, et al. Noncytotoxic drug therapy in children with unresectable desmoid tumors. Cancer 1997;80: 334-340.
132. Kyasa MJ. Phase II trial of tamoxifen and interferon alpha in patients with metastatic or recurrent soft tissue sarcoma [abstract]. J Clin Oncol 2004;22(14 suppl): Abstract 9031.
133. Chao AS, Lai CH, Hsueh S, et al. Successful treatment of recurrent pelvic desmoid tumor with tamoxifen: case report. Hum Reprod 2000;15:311-313.
134. Hansmann A, Adolph C, Vogel T, et al. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 2004;100:612-620.
135. Leithner A, Schnack B, Katterschafka T, et al. Treatment of extra-abdominal desmoid tumors with interferon-alpha with or without tretinoin. J Surg Oncol 2000;73:21-25.
136. Azzarelli A, Gronchi A, Bertulli R, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 2001;92:1259-1264.
137. Weiss AJ, Lackman RD. Low-dose chemotherapy of desmoid tumors. Cancer 1989;64:1192-1194.
138. Seiter K, Kemeny N. Successful treatment of a desmoid tumor with doxorubicin. Cancer 1993;71:2242-2244.
139. Patel SR, Evans HL, Benjamin RS. Combination chemotherapy in adult desmoid tumors. Cancer 1993;72: 3244-3247.
140. Lynch HT, Fitzgibbons R, Chong S, et al. Use of doxorubicin and dacarbazine for the management of unresectable intra-abdominal desmoid tumors in Gardner's syndrome. Dis Colon Rectum 1994;37:260-267.
141. Gega M, Yanagi H, Yoshikawa R, et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 2006;24:102-105.
142. Mace J, Sybil Biermann J, Sondak V, et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002;95:2373-2379.
143. Heinrich MC, McArthur GA, Demetri GD, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006;24:1195-1203.
144. Chugh R, Maki RG, Thomas DO, et al. A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis [abstract]. J Clin Oncol 2006;24(18 suppl): Abstract 9515.